Through creation of products for its pharmaceutical division, AXIM has byproducts that are being sold on the nutraceutical market
AXIM is actively involved in the research and development of innovative pharmaceutical delivery systems and active pharmaceutical ingredients (API).
AXIM boasts 5 issued patents and 10 more filed, as well as 28 trademarks in its Intellectual Property Portfolio
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy.
AXIM® Biotechnologies, Inc. is a world leader in the research and development of cannabinoid-based pharmaceutical products.
Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.